| April 1, 2028 |
JAZZ |
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 |
Trial Milestone |
Phase 1 |
| April 1, 2028 |
ALNY |
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran |
Trial Milestone |
Phase 2 |
| April 6, 2028 |
AZN |
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus |
Trial Milestone |
Phase 3 |
| April 6, 2028 |
TAK |
A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC) |
Trial Milestone |
Phase 1 |
| April 15, 2028 |
LLY |
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity |
Trial Milestone |
Phase 3 |
| April 15, 2028 |
LLY |
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study |
Trial Milestone |
Phase 3 |
| April 15, 2028 |
LLY |
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma |
Trial Milestone |
Phase 2 |
| April 15, 2028 |
LLY |
A Study of Brenipatide in Participants With Alcohol Use Disorder |
Trial Milestone |
Phase 3 |
| April 15, 2028 |
ABBV |
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) |
Trial Milestone |
Phase 1 |
| April 15, 2028 |
ARGX |
A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
Trial Milestone |
Phase 2/Phase 3 |
| April 15, 2028 |
NBIX |
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada |
Trial Milestone |
Phase 3 |
| April 15, 2028 |
RVMD |
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors |
Trial Milestone |
Phase 1 |
| April 15, 2028 |
SMMT |
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 |
Trial Milestone |
Phase 3 |
| April 15, 2028 |
VIR |
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers |
Trial Milestone |
Phase 1/Phase 2 |
| April 15, 2028 |
RYTM |
A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) |
Trial Milestone |
Phase 2 |
| April 15, 2028 |
RCUS |
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma |
Trial Milestone |
Phase 3 |
| April 15, 2028 |
TARA |
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer |
Trial Milestone |
Phase 3 |
| April 15, 2028 |
BCAX |
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
Trial Milestone |
Phase 2/Phase 3 |
| April 15, 2028 |
ERAS |
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) |
Trial Milestone |
Phase 3 |
| April 17, 2028 |
ONC |
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
Trial Milestone |
Phase 3 |
| April 19, 2028 |
AMGN |
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta |
Trial Milestone |
Phase 3 |
| April 25, 2028 |
NVS |
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. |
Trial Milestone |
Phase 3 |
| April 26, 2028 |
TEVA |
A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo |
Trial Milestone |
Phase 1 |
| April 27, 2028 |
REGN |
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition |
Trial Milestone |
Phase 2 |
| April 28, 2028 |
JAZZ |
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer |
Trial Milestone |
Phase 3 |
| April 29, 2028 |
ONC |
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors |
Trial Milestone |
Phase 1 |
| April 30, 2028 |
IDYA |
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| April 30, 2028 |
VRCA |
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) |
Trial Milestone |
Phase 3 |
| April 30, 2028 |
RGNX |
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) |
Trial Milestone |
Phase 3 |
| April 30, 2028 |
RLAY |
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer |
Trial Milestone |
Phase 3 |